Description
Application
Thiamet G has been used as an O-GlcNAcase inhibitor:
to treat human embryonic kidney 293 cells in order to study its effect on Wnt/beta-catenin signalling
to treat lytically-replicating producer
to incubate mice (C57BL/6) aortic segments to increase global O-GlcNAc levels
Biochem/physiol Actions
Thiamet G is a glycosidase inhibitor
Thiamet G is a potent inhibitor of the enzyme O-GlcNAcase (Ki = 21 nM). The compound is orally bioavailable and crosses the blood brain barrier. Thiamet G leads to an increase in O-GlcNAc-modified proteins in cell-based and in vivo assay systems, and reduces levels of phosphorylated Tau protein in rat cortex and hippocampus.